Search Results - "Ovarian Neoplasms - pathology"

The Origin and Pathogenesis of Endometriosis by Wang, Yeh, Nicholes, Kristen, Shih, Ie-Ming

“… Once formed, the ectopic tissue becomes subject to immune surveillance, resulting in chronic inflammation…”
Get more information

Origin and molecular pathogenesis of ovarian high-grade serous carcinoma by Kurman, R J

“…A new paradigm for the pathogenesis of ovarian cancer has recently been proposed which helps to explain persistent problems in describing the development and…”
Get more information

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer by Westin, Shannon N, Labrie, Marilyne, Litton, Jennifer K, Blucher, Aurora, Fang, Yong, Vellano, Christopher P, Marszalek, Joseph R, Feng, Ningping, Ma, XiaoYan, Creason, Allison, Fellman, Bryan, Yuan, Ying, Lee, Sanghoon, Kim, Tae-Beom, Liu, Jinsong, Chelariu-Raicu, Anca, Chen, Tsun Hsuan, Kabil, Nashwa, Soliman, Pamela T, Frumovitz, Michael, Schmeler, Katheleen M, Jazaeri, Amir, Lu, Karen H, Murthy, Rashmi, Meyer, Larissa A, Sun, Charlotte C, Sood, Anil K, Coleman, Robert L, Mills, Gordon B

“…On the basis of strong preclinical rationale, we sought to confirm recommended phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT…”
Get more information

Surgery in recurrent ovarian cancer by Sehouli, Jalid, Grabowski, Jacek P.

“… The surgical management of recurrent disease is still subject to an emotional international discussion…”
Get full text

Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging by Zhou, Zijian, Wang, Lirong, Chi, Xiaoqin, Bao, Jianfeng, Yang, Lijiao, Zhao, Wenxiu, Chen, Zhong, Wang, Xiaomin, Chen, Xiaoyuan, Gao, Jinhao

“…) nanoparticles, which exhibit a strong T1 contrast effect for tumor imaging through enhanced permeation and retention effect and the ability to clear out of the body in living subjects…”
Get full text

Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples by Riester, Markus, Wei, Wei, Waldron, Levi, Culhane, Aedin C, Trippa, Lorenzo, Oliva, Esther, Kim, Sung-Hoon, Michor, Franziska, Huttenhower, Curtis, Parmigiani, Giovanni, Birrer, Michael J

“… We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested…”
Get more information

Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review by Moro, Francesca, Ciancia, Marianna, Zace, Drieda, Vagni, Marica, Tran, Huong Elena, Giudice, Maria Teresa, Zoccoli, Sofia Gambigliani, Mascilini, Floriana, Ciccarone, Francesca, Boldrini, Luca, D'Antonio, Francesco, Scambia, Giovanni, Testa, Antonia Carla

“…%) on other malignancies. Most studies were at high risk of bias for subject selection (i.e., sample size, source, or scanner model were not specified…”
Get full text

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction by Le, Dung T, Brockstedt, Dirk G, Nir-Paz, Ran, Hampl, Johannes, Mathur, Shruti, Nemunaitis, John, Sterman, Daniel H, Hassan, Raffit, Lutz, Eric, Moyer, Bentley, Giedlin, Martin, Louis, Jana-Lynn, Sugar, Elizabeth A, Pons, Alice, Cox, Andrea L, Levine, Jordana, Murphy, Aimee Luck, Illei, Peter, Dubensky, Jr, Thomas W, Eiden, Joseph E, Jaffee, Elizabeth M, Laheru, Daniel A

“… These two phase I studies test ANZ-100 and CRS-207 in subjects with liver metastases and mesothelin-expressing cancers, respectively…”
Get more information

miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway by Salem, Mohamed, O'Brien, Jacob A, Bernaudo, Stefanie, Shawer, Heba, Ye, Gang, Brkić, Jelena, Amleh, Asma, Vanderhyden, Barbara C, Refky, Basel, Yang, Burton B, Krylov, Sergey N, Peng, Chun

“… Interestingly, plasma levels of miR-590-3p were significantly higher in patients with EOC than in subjects with benign gynecologic disorders…”
Get more information

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials by Skates, Steven J, Greene, Mark H, Buys, Saundra S, Mai, Phuong L, Brown, Powel, Piedmonte, Marion, Rodriguez, Gustavo, Schorge, John O, Sherman, Mark, Daly, Mary B, Rutherford, Thomas, Brewster, Wendy R, O'Malley, David M, Partridge, Edward, Boggess, John, Drescher, Charles W, Isaacs, Claudine, Berchuck, Andrew, Domchek, Susan, Davidson, Susan A, Edwards, Robert, Elg, Steven A, Wakeley, Katie, Phillips, Kelly-Anne, Armstrong, Deborah, Horowitz, Ira, Fabian, Carol J, Walker, Joan, Sluss, Patrick M, Welch, William, Minasian, Lori, Horick, Nora K, Kasten, Carol H, Nayfield, Susan, Alberts, David, Finkelstein, Dianne M, Lu, Karen H

“… Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject's baseline, which triggered transvaginal ultrasound…”
Get more information

A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses by Irajizad, Ehsan, Han, Chae Y, Celestino, Joseph, Wu, Ranran, Murage, Eunice, Spencer, Rachelle, Dennison, Jennifer B, Vykoukal, Jody, Long, James P, Do, Kim Anh, Drescher, Charles, Lu, Karen, Lu, Zhen, Bast, Robert C, Hanash, Sam, Fahrmann, Johannes F

“…] was developed for distinguishing early-stage ovarian cancer from BPM. The performance of the metabolite panel was evaluated in an independent set of sera from 118 ovarian cancer cases and 56 subjects…”
Get more information

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study by Monk, Bradley J., Kauderer, James T., Moxley, Katherine M., Bonebrake, Albert J., Dewdney, Summer B., Secord, Angeles Alvarez, Ueland, Frederick R., Johnston, Carolyn M., Aghajanian, Carol

“… ≤ 2, and one prior platinum containing regimen were eligible. A two-stage design was utilized with a target sample size of 22 and 30 subjects, respectively…”
Get full text

USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression by Chen, Dejia, Zhao, Yue, Zhang, Xiaobo, Shi, Xiaocheng, Liu, Yiming, Lou, Ge

“…Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of…”
Get full text

Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations by Trabert, Britton, Waterboer, Tim, Idahl, Annika, Brenner, Nicole, Brinton, Louise A, Butt, Julia, Coburn, Sally B, Hartge, Patricia, Hufnagel, Katrin, Inturrisi, Federica, Lissowska, Jolanta, Mentzer, Alexander, Peplonska, Beata, Sherman, Mark E, Wills, Gillian S, Woodhall, Sarah C, Pawlita, Michael, Wentzensen, Nicolas

“… (244 ovarian cancers/556 control subjects) and 2) a prospective nested case-control study in the PLCO Cancer Screening Trial…”
Get more information

Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway by Guo, Yi, Cui, Wei, Pei, Yuqing, Xu, Danfei

“…To test whether platelets could increase invasion potential and initiate EMT in ovarian cancer cells via a TGF-β signaling pathway. Blood samples were…”
Get full text

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population by Song, Honglin, Cicek, Mine S, Dicks, Ed, Harrington, Patricia, Ramus, Susan J, Cunningham, Julie M, Fridley, Brooke L, Tyrer, Jonathan P, Alsop, Jennifer, Jimenez-Linan, Mercedes, Gayther, Simon A, Goode, Ellen L, Pharoah, Paul D P

“… Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation…”
Get more information

Mechanisms of Ovarian Cancer-Associated Cachexia by Callaway, Chandler S, Mouchantat, Lila M, Bitler, Benjamin G, Bonetto, Andrea

“… In clinical studies, there is increased evidence that reduced skeletal muscle mass and quality associate with worse outcomes in subjects with ovarian cancer…”
Get more information

Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting by Oberg, Ann L., Heinzen, Ethan P., Hou, Xiaonan, Al Hilli, Mariam M., Hurley, Rachel M., Wahner Hendrickson, Andrea E., Goergen, Krista M., Larson, Melissa C., Becker, Marc A., Eckel-Passow, Jeanette E., Maurer, Matthew J., Kaufmann, Scott H., Haluska, Paul, Weroha, S. John

“…Repeated measures studies are frequently performed in patient-derived xenograft (PDX) models to evaluate drug activity or compare effectiveness of cancer…”
Get full text

RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non‐Metastatic Ovarian Cancer in Mice by Pin, Fabrizio, Jones, Alexander J, Huot, Joshua R, Narasimhan, Ashok, Zimmers, Teresa A, Bonewald, Lynda F, Bonetto, Andrea

“…ABSTRACT Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We…”
Get full text

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors by Rudnick, Stephen I, Lou, Jianlong, Shaller, Calvin C, Tang, Yong, Klein-Szanto, Andres J P, Weiner, Louis M, Marks, James D, Adams, Gregory P

“…Antibody drugs are widely used in cancer therapy, but conditions to maximize tumor penetration and efficacy have yet to be fully elucidated. In this study, we…”
Get more information